CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced insulin for months without the patient needing to take immunosuppressants.

CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of ...

Pigs Modified With CRISPR Gene-Editing Technology Could Be Available For Human Consumption Very Soon TwistedSifter Battery ...

The model is built on CRISPR technology, a powerful gene editing tool used to edit genomes and develop therapies for genetic diseases. However, training to use this tool for designing experiments can ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best biotech stocks to buy. Following CRISPR Therapeutics AG ...

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout ...